Filing Details

Accession Number:
0001209191-20-052334
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-09-29 16:33:05
Reporting Period:
2020-09-25
Accepted Time:
2020-09-29 16:33:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1699382 Pmv Pharmaceuticals Inc. PMVP () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1207833 L Arnold Oronsky C/O Pmv Pharmaceuticals, Inc.
8 Clarke Drive, Suite 3
Cranbury NJ 08512
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-09-25 55,000 $18.00 55,000 No 4 P Indirect See footnote
Common Stock Acquisiton 2020-09-29 1,620,101 $0.00 1,675,101 No 4 C Indirect See footnote
Common Stock Acquisiton 2020-09-29 3,488,398 $0.00 5,163,499 No 4 C Indirect See footnote
Common Stock Acquisiton 2020-09-29 1,040,654 $0.00 6,204,153 No 4 C Indirect See footnote
Common Stock Acquisiton 2020-09-29 265,203 $0.00 6,469,356 No 4 C Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series Seed Preferred Stock Disposition 2020-09-29 1,620,101 $0.00 1,620,101 $0.00
Common Stock Series A Preferred Stock Disposition 2020-09-29 3,488,398 $0.00 3,488,398 $0.00
Common Stock Series B Preferred Stock Disposition 2020-09-29 1,040,654 $0.00 1,040,654 $0.00
Common Stock Series C Preferred Stock Disposition 2020-09-29 265,203 $0.00 265,203 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
  2. The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.